Abstract
Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America.
Highlights
Antimicrobial resistance is a threat to public health
95.8% (2158/2252) of the isolates were susceptible to CZA (minimum inhibitory concentration of 90% of isolates (MIC90 ) ≤1 mg/L)
This study showed that 95.8% of clinical isolates of Enterobacterales from five Latin American countries, collected between January 2016 and October 2017, were susceptible to CZA (MIC90 ≤ 1 mg/L)
Summary
Antimicrobial resistance is a threat to public health. Enterobacterales are some of the most common and pathogenic microorganisms that have acquired resistance to several classes of antimicrobials [1]. concerning is the resistance to carbapenems since these agents are often considered the lastAntibiotics 2020, 9, 62; doi:10.3390/antibiotics9020062 www.mdpi.com/journal/antibioticsAntibiotics 2020, 9, 62 resort antibiotics. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam inhibitor capable of inhibiting several class D, C and A β-lactamases, including the KPC-family enzymes. High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. We evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
